Quick Facts
Plain-English Summary
Semaglutide is a long-acting synthetic analogue of native glucagon-like peptide-1, an incretin hormone secreted by intestinal L-cells in response to food intake. Where native GLP-1 is rapidly degraded by the enzyme DPP-4 with a half-life of approximately two minutes, semaglutide's structural modifications — an aminoisobutyric acid substitution at position 8 and a C18 fatty di-acid chain attached via a linker at Lys26 — allow it to bind albumin in the bloodstream and resist enzymatic breakdown, extending its effective half-life to approximately seven days. This pharmacokinetic profile supports once-weekly subcutaneous dosing.
The compound acts as a full agonist at the GLP-1 receptor (GLP-1R), which is expressed across multiple tissue types including pancreatic beta cells, the hypothalamus, the gastrointestinal tract, and the cardiovascular system. The clinical consequence of sustained GLP-1R activation is a coordinated metabolic effect: enhanced glucose-dependent insulin secretion, suppressed glucagon release, slowed gastric emptying, and reduced appetite signalling via central nervous system pathways. Together these mechanisms produce the glycaemic control and body weight reduction observed in clinical trials.
Semaglutide is FDA-approved under three branded products: Ozempic (subcutaneous, 2017) for type 2 diabetes and cardiovascular risk reduction; Rybelsus (oral tablet, 2019) for type 2 diabetes; and Wegovy (subcutaneous, higher dose, 2021) for chronic weight management. The clinical trial programme supporting these approvals is among the largest assembled for any metabolic compound, comprising the SUSTAIN series (glycaemic endpoints), the STEP series (weight loss endpoints), and the SELECT trial (cardiovascular outcomes). Compounded semaglutide became widely used in research and clinical contexts during the branded drug shortage of 2022–2024; the FDA cleared the shortage designation in 2024.
Unlike most compounds profiled on CompoundProfile, semaglutide carries full FDA approval for multiple indications and is supported by multiple large Phase III randomised controlled trials published in peer-reviewed journals. Its evidence base reflects the highest standard available in clinical pharmacology.
The compounded semaglutide described on this page is produced by independent compounding facilities and is not a Novo Nordisk product. Its formulation, excipients, and quality may differ from branded products. For research contexts this distinction is material: the active molecule is identical in structure, but potency, sterility, and stability profiles should be verified via certificate of analysis from a qualified testing laboratory.
Mechanism of Action
Proposed mechanisms below are derived from in vitro and rodent studies only. No mechanistic pathway has been validated in a controlled human study.
All mechanistic data is derived from in vitro or rodent studies. Applicability of these pathways in humans is not established.
Animal Data
| Model | Finding | ICPS Status |
|---|
No finding from this section has been replicated in a controlled human trial. Animal-to-human translation for peptides is uncertain and cannot be assumed.
Human Trials
| Trial | Population | Status | ICPS Status |
|---|---|---|---|
| STEP 1 (Wegovy approval) | 1,961 adults with obesity (BMI ≥30) or overweight (BMI ≥27 + comorbidity), 68 weeks, semaglutide 2.4 mg SC weekly vs. placebo + lifestyle intervention. Mean body weight reduction: 14.9% (semaglutide) vs. 2.4% (placebo). 86.4% of semaglutide participants achieved ≥5% weight loss. Wilding et al. NEJM 2021 ↗ | — | Phase III RCT |
| SELECT (CV outcomes) | 17,604 adults with overweight/obesity + established cardiovascular disease (no T2DM), semaglutide 2.4 mg SC weekly vs. placebo. Primary endpoint (MACE): 20% relative risk reduction (HR 0.80; 95% CI 0.72–0.90). Median follow-up 34.2 months. First dedicated CV outcomes trial in non-diabetic obesity. Lincoff et al. NEJM 2023 ↗ | — | Phase III RCT |
| SUSTAIN 1–10 (Ozempic approval) | Series of Phase III trials in T2DM patients. Across the programme: HbA1c reduction of 1.5–2.0%; body weight reduction of 4–6 kg; SUSTAIN-6 showed 26% reduction in CV death + non-fatal MI or stroke vs. placebo (HR 0.74; 95% CI 0.58–0.95). Supported FDA approval of Ozempic in 2017. Marso et al. NEJM 2016 ↗ | — | Phase III RCT |
| STEP 4 (discontinuation) | 803 adults who achieved ≥5% weight loss on semaglutide over 20 weeks, then randomised to continue semaglutide or switch to placebo for 48 weeks. Participants who discontinued regained two-thirds of prior weight loss. Confirms the need for ongoing treatment to maintain effect. Rubino et al. JAMA 2021 ↗ | — | Phase III RCT |
| PIONEER (Rybelsus approval) | Series of trials evaluating oral semaglutide (3, 7, 14 mg daily). PIONEER-6 showed HbA1c reduction of ~1.4% and non-inferior cardiovascular safety vs. placebo in T2DM. Supported FDA approval of Rybelsus (oral semaglutide) in 2019. | — | Phase III RCT |
GLP-1 / Semaglutide has no FDA, EMA, or Health Canada–approved indications and no published Phase III trial data for any condition as of 2026.
Safety & Side Effects
Nausea and vomiting are the most common adverse events, reported in 30–40% of participants in STEP and SUSTAIN trials. Effects are dose-dependent, typically peak during dose titration, and attenuate over 4–8 weeks in most patients. Diarrhoea (20%) and constipation (10–15%) are also reported. Slow titration schedules (starting at 0.25 mg) are standard of care specifically to reduce GI burden.
GLP-1R is expressed in rodent thyroid C-cells, and semaglutide induces dose-dependent C-cell hyperplasia and tumours in rodent carcinogenicity studies. Human thyroid C-cells express GLP-1R at much lower density. No causal relationship between GLP-1 agonists and medullary thyroid carcinoma has been established in humans. Semaglutide carries a boxed warning and is contraindicated in individuals with personal or family history of MTC or MEN-2.
- Pancreatitis reported at low absolute rates in trials; FDA label includes a precaution
- Causality not definitively established — T2DM itself confers elevated pancreatitis risk
- Discontinue if pancreatitis suspected
- Contraindicated in individuals with history of pancreatitis
- No evidence of increased pancreatic cancer risk in completed trials
- Personal or family history of medullary thyroid carcinoma
- Multiple Endocrine Neoplasia syndrome type 2 (MEN-2)
- History of pancreatitis
- Pregnancy or breastfeeding (discontinue ≥2 months before planned conception)
- Severe renal impairment (use with caution)
- Concurrent use of other GLP-1 receptor agonists
- Insulin use without medical supervision (hypoglycaemia risk)
GLP-1 / Semaglutide is not approved by the FDA, EMA, or Health Canada for any medical indication. It is classified as a research compound and is not legal for human therapeutic use in most jurisdictions. Procurement and use outside of registered clinical trials carries regulatory and unknown health risks.
References
Research disclaimer. CompoundProfile publishes summaries of available scientific literature for educational purposes only. This page does not constitute medical advice and should not be interpreted as an endorsement of GLP-1 / Semaglutide for any therapeutic use. Consult a licensed healthcare professional before considering any research compound. All evidence gradings reflect the state of published literature as of August 2026 and are assessed independently by ICPS.
Community Commentary
Selected discussion from r/Peptides · Curated for signal, not volume
Worth being precise about what the SELECT trial actually showed. The 20% MACE reduction was in a non-diabetic obese population with established CVD — a very specific subset. The absolute risk reduction was about 1.5 percentage points over 34 months. That's clinically meaningful but a very different statement than "GLP-1 prevents heart attacks." The mechanism is also genuinely unclear — the effect appears to exceed what weight loss alone would predict, but unpacking how much is direct GLP-1R cardiac signalling vs. plaque stabilisation vs. metabolic improvement is still active research.
Agreed. The MACE signal preceded meaningful weight separation in some of the earlier SUSTAIN-6 data, which does suggest a weight-independent mechanism. GLP-1R is expressed in macrophages and can modulate inflammatory cytokines, and there's a decent body of preclinical data on GLP-1R effects on atherosclerotic plaque. None of it is definitive, but it's plausible. The clinical magnitude of the CV benefit is the more reliable data point — the mechanism stays contested.
The shortage era 2022–2024 created a lot of confusion about what compounded semaglutide is. The molecule is identical to what's in Ozempic — same CAS, same sequence — but the formulation, manufacturing controls, and excipients vary enormously by pharmacy. The FDA issued multiple warning letters over that period about potency errors and unlabelled additives (some pharmacies were including B12 or NAD+ without disclosure). The branded shortage cleared in 2024, which closed the 503A/503B pathway for most commercial compounders. Research use is a different context with different documentation requirements.
The STEP 4 discontinuation data is the most important piece that social media consistently buries. Two-thirds of the weight lost comes back within 12 months of stopping. This is not a drug that induces permanent metabolic reprogramming — it's appetite suppression that works while you're on it. That's not a criticism; it's how most effective pharmacological interventions work. But the narrative that "you take it for a year and you're fixed" is factually wrong according to the data we have, and prescribers have a responsibility to set those expectations clearly.
This is accurate, and it's why the STEP 4 authors described obesity as a chronic disease requiring ongoing management — analogous to hypertension or hyperlipidaemia, not an acute condition. The regain data doesn't undermine the efficacy of semaglutide; it reframes what the treatment actually is. Long-term use in appropriate populations is the intended model.
From a peptide chemistry perspective, semaglutide is among the most structurally complex peptides in routine research use. The albumin-binding fatty acid chain is attached via a complex linker chemistry — it's not a simple linear peptide synthesis product. Analytical verification matters more here than for simpler peptides. HPLC alone may not capture all impurities. Mass spec confirmation of the correct molecular weight (4113.6 Da) and appropriate purity grading is the minimum reasonable standard for any batch intended for research injection. COA from an independent third-party lab, not the manufacturer's in-house testing, is the defensible approach.